2016
DOI: 10.1080/14737175.2016.1243056
|View full text |Cite
|
Sign up to set email alerts
|

The future of multiple sclerosis treatments

Abstract: A note on versions:The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 191 publications
(203 reference statements)
0
3
0
Order By: Relevance
“…As a group, patients with MS are treated with a multitude of drugs to manage their disease and its symptoms. These include disease-modifying drugs, corticosteroids, and numerous agents to manage symptoms such as anxiety, depression, fatigue, pain, sleep disorders, bladder problems, and spasticity (Coclitu, Constantinescu, & Tanasescu, 2016;Vermersch, 2015).…”
Section: Msmentioning
confidence: 99%
“…As a group, patients with MS are treated with a multitude of drugs to manage their disease and its symptoms. These include disease-modifying drugs, corticosteroids, and numerous agents to manage symptoms such as anxiety, depression, fatigue, pain, sleep disorders, bladder problems, and spasticity (Coclitu, Constantinescu, & Tanasescu, 2016;Vermersch, 2015).…”
Section: Msmentioning
confidence: 99%
“…Teriflunomide primarily acts as an inhibitor of dihydroorotate-dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells such as T- and B-lymphocytes, thereby diminishing the inflammatory response to auto-antigens ( 137 ). A comprehensive analysis of selected drugs presented in Figures 2 , 3 are in previous reviews ( 32 , 96 , 138 , 139 ).…”
Section: A Glimpse Of Hope For Progressive Multiple Sclerosismentioning
confidence: 99%
“…(Rebif®), received approval for clinical use. However, many more emerging DMTs are been investigated in order to cover the unmet need for treating neurodegeneration and halting the progression of MS disability (Coclitu, Constantinescu, & Tanasescu, 2016).…”
Section: General Section 1 Introduction 11 a Brief Historical Overview Of Multiple Sclerosismentioning
confidence: 99%